Chimeric Therapeutics (ASX:CHM) Receivables Turnover : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Chimeric Therapeutics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Chimeric Therapeutics's average Accounts Receivable for the six months ended in Dec. 2023 was A$5.27 Mil.

Chimeric Therapeutics Receivables Turnover Historical Data

The historical data trend for Chimeric Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Receivables Turnover Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Receivables Turnover

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Chimeric Therapeutics's Receivables Turnover

For the Biotechnology subindustry, Chimeric Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Receivables Turnover falls into.

Chimeric Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Chimeric Therapeutics's Receivables Turnover for the fiscal year that ended in Jun. 2023 is calculated as

	Receivables Turnover (A: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2023 )	/ (	(Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )
=	0	/ (	(2.658	+	0.027)	/	2 )
=	0	/	1.3425
=	N/A

Chimeric Therapeutics's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	0	/ (	(0.027	+	10.521)	/	2 )
=	0	/	5.274
=	N/A

Chimeric Therapeutics (ASX:CHM) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Chimeric Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines